ImmuCell vs RxSight
RxSight reported revenue of $134 million in fiscal 2025, 4.9 times ImmuCell's $28 million in fiscal 2025. ImmuCell's revenue grew 4.3% in its latest year, and RxSight's fell 3.9%. ImmuCell had an operating margin of 6.0%, against -35.8% at RxSight. Free cash flow was $1 million at ImmuCell and −$19 million at RxSight.
Side by side
| ImmuCell | RxSight | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $28M | $134M |
| Revenue growth | 4.3% | −3.9% |
| Revenue growth a year, last 5 years | 12.5% | 55.7% |
| Gross margin | 41.4% | 76.6% |
| Operating margin | 6.0% | −35.8% |
| Net margin | −3.8% | −29.0% |
| Free cash flow | $1M | −$19M |
| Free cash flow margin | 4.4% | −14.4% |
| Return on capital | — | −82.9% |
| Net debt to EBITDA | 1.2x | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 10.5% | 5.1% |
| Last close | $11.17 | $4.61 |
| P/E at the last close | 58.8× | — |
| Insider trades, last 12 months | bought $140,146, sold $0 | sold $103,745 |
| Piotroski F-score | — | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ImmuCellRxSight
Operating margin
Percent of revenue
ImmuCellRxSight
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ImmuCellRxSight